Page 1526 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 85 T-Cell Lymphomas 1353

TABLE Summary of Retrospective Up-Front Studies in Peripheral T-Cell Lymphoma
85.2
Regimen PTCL Subtypes n CR (%) OS
Anthracycline based NK/T nasal 24 66.7 Not reported
Anthracycline based PTCL-NOS 24 69.6 2 years: 63%
NK/T nasal 51 56.0 2 years: 43%
Anthracycline based PTCL-combined 174 49.0 4 years: 38%
PTCL-NOS 95 47.0 4 years: 32%
ALCL 30 69.0
AITL 22 37.0
NK/T nasal 14 46.0
EATL 12 27.0
CHOP-like AITL 33 60.6 5 years: 36%
CHOP type ± RT NK/T nasal 7 28.6
CMT NK/T nasal 61 65.6 5 years: 41%
CHOP ± RT PTCL-combined 78 52.6 5 years: 36%
ALCL 13 69.2
PTCL-NOS 31 51.6
AITL 5 40.0
NK/T nasal 25 52.0
Anthracycline based PTCL-combined 66 62.0 5 years: 55%
ALCL 19 79.0
PTCL-NOS 28 60.7
AITL 7 28.6
Adriamycin based Non-ALCL PTCL 96 5 years: 26%
Anthracycline based + RT NK/T nasal 47 65.9
CHOP based NK/T nasal local 18 50.0 5 years: 15%
CHOP based + RT NK/T nasal local 27 74.1 5 years: 59%
CHOP based NK/T nasal systemic 10 60.0 5 years: 30%
CHOP based + RT NK/T nasal systemic 10 30.0 5 years: 20%
CHOP type PTCL-Nos 117 64.1 5 years: 35%
ALCL 33 55.0 5 years: 43%
AITL 10 70.0 5 years: 36%
NK/T nasal 17 73.0 5 years: 24%
EATL 9 33.0 5 years: 22%
CT + RT NK/T nasal 16 5 years: 42%
CT NK/T nasal 15 5 years: 20%
CHOP Non-ALCL PTCL 24 58.0 3 years: 43%
CHOP intensive Non-ALCL PTCL 52 59.0 3 years: 49%
CHOP/COPBLAM-V + RT NK/T nasal 16 37.5 5 years: 59%
RT NK/T nasal 33 52.0 5 years: 76%
CHOP type PTCL-combined 125 53.0 5 years: 43%
ALCL 21 71.0 5 years: 61%
PTCL-NOS 70 55.0 5 years: 45%
AITL 34 36.0 5 years: 28%
CHOP based + RT NK/T nasal 71 84.5 5 years: 76%
CHOP alone NK/T nasal 3 33.3
Anthracycline-based PTCL-NOS 340 5 years: 32%
ALK-negative 72 5 years: 49%
ALCL 243 5 years: 32%
AITL 136 5 years: 42%
NK/T nasal 62 3 years: 20%
EATL
AITL, Angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; CHOP, cyclophosphamide, hydroxydaunomycin, vincristine (Oncovin), and
prednisone; CMT, combined modality therapy; COPBLAM-V, cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin, doxorubicin (Adriamycin), and
procarbazine; CR, complete remission; CT, chemotherapy; EATL, enteropathy-associated T-cell lymphoma; NK, natural killer; NOS, not otherwise specified; OS, overall
survival, PTCL, peripheral T-cell lymphoma; RT, radiotherapy.